Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug

• Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November. 
• This marks LillyDirect’s first retail collaboration and is aimed at offering patients flexibility in how they access the drug, the company said.
   

Eli Lilly and Company (LLY) on Wednesday announced a collaboration with Walmart Inc. (WMT) to expand access to lower pricing for its popular weight-loss drug Zepbound, available through its digital health platform LillyDirect.

Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November, the company said. This marks LillyDirect’s first retail collaboration and is aimed at offering patients flexibility in how they access the drug, the company said.

How Will It Work?

Customers can have their prescriptions routed to LillyDirect Self Pay Pharmacy Solutions through their health care provider's electronic health record system, and then choose to have the drug delivered to home via LillyDirect or pick it a at one of the 4,600 Walmart Pharmacies across the U.S., the company said. The price for Zepbound will remain the same regardless of the customer's choice.

Zepbound single-dose vials will be available in all approved strengths, with the lowest dose starting at $349 per month with self-pay, the company said. All other doses, including 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg of Zepbound, are priced at $499 per month.

LillyDirect Gains Popularity

Zepbound, containing Tirzepatide, reduces appetite and the amount a person eats to induce weight loss. Lilly started offering highest approved doses of Zepbound at discounted prices to cash-paying customers on Lillydirect in June to expand access.

According to Lilly, approximately 35% of new Zepbound prescriptions were fulfilled through LillyDirect in the second quarter. On Wednesday, the company also committed to exploring further options to broaden patient access.

On Stocktwits, retail sentiment around LLY stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.

LLY stock is up by 6% this year, while WMT has gained 14%. 

Read also: Thermo Fisher Adds Clario Holdings In A $9.4B Deal – Its Third Acquisition In 2025

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on